|Related Categories||Agonists, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Biochemicals and Reagents, CI-CY,|
|optical activity||[α]/D +100 to +120°, c = 0.025 mg/mL in methanol|
|solubility||DMSO: ≥5 mg/mL|
|storage temp.||room temp|
CP-135807 is a selective 5-HT1D agonist.
Sold for research purposes under agreement from Pfizer Inc.
Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. Rollema H, Clarke T, Sprouse JS, et al. J. Neurochem. 67(5), 2204-7, (1996)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?